OCX - OncoCyte Corporation
| Previous Close | 1.5300 |
| Open | 1.5200 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 1.5075 - 1.5815 |
| 52 Week Range | 1.1000 - 4.5950 |
| Volume | 44,371 |
| Avg. Volume | 36,796 |
| Market Cap | 61.81M |
| Beta (3Y Monthly) | 2.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.43 |
| Earnings Date | Feb 27, 2019 - Mar 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.69 |
- Markit•19 hours ago
See what the IHS Markit Score report has to say about OncoCyte Corp.
# OncoCyte Corp ### NYSE MKT:OCX View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for OCX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting OCX. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $678 million over the last one-month into ETFs that hold OCX are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•13 days ago
OncoCyte Announces Transition to Ion Torrent Next-Generation Sequencing Platform
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced its successful transition to the Ion GeneStudio S5 next-generation sequencing (NGS) platform for targeted sequencing. The platform was chosen by OncoCyte after evaluating four leading platforms. OncoCyte anticipates that the use of the Ion GeneStudio S5 System will increase the likelihood that DetermaVu™ will offer the consistent and robust results necessary for product development and further studies.
- GlobeNewswire•26 days ago
OncoCyte Provides Progress Update on Ongoing Studies
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that it has run all of the 700 samples required for its Algorithm Development Study, which is intended to derive the proprietary mathematical algorithm that will be used to interpret the results of the DetermaVu™ assay. The data from the samples is being analyzed by biostatisticians who are developing the algorithm, and once completed and optimized, OncoCyte will use the algorithm to carry out its R&D Validation study. The Company has also run the 250 blinded, prospectively-collected patient blood samples to be used for its R&D Validation study, which is designed to confirm the performance of the proprietary algorithm on a blinded set of samples.
- Markit•27 days ago
See what the IHS Markit Score report has to say about OncoCyte Corp.
# OncoCyte Corp ### NYSE MKT:OCX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for OCX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting OCX. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding OCX are favorable, with net inflows of $1.57 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•2 months ago
OncoCyte Corporation to Present at the LD Micro 11th Annual Main Event Investor Conference
ALAMEDA, Calif., Nov. 30, 2018 -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced.
Markit•2 months agoSee what the IHS Markit Score report has to say about OncoCyte Corp.
OncoCyte Corp NYSE MKT:OCX
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Summit Midstream Partners, LP, Empire State Realty Trust, Expeditors International of Washington, Ellington Residential Mortgage REIT, OncoCyte, and Sachem Capital — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
OncoCyte Corporation to Present at the Piper Jaffray 30th Annual Health Care Conference
ALAMEDA, Calif., Nov. 19, 2018 -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced.
- Associated Press•2 months ago
OncoCyte: 3Q Earnings Snapshot
On a per-share basis, the Alameda, California-based company said it had a loss of 7 cents. In the final minutes of trading on Tuesday, the company's shares hit $1.82. A year ago, they were trading at $5.95. ...
- GlobeNewswire•2 months ago
OncoCyte Reports Third Quarter 2018 Financial Results and Progress in DetermaVu™ Development
Transition to New Diagnostic Testing Platform Complete Prospective R&D Validation Study Results Expected by Late 2018 or Early 2019 Development Plan Remains On-Track,.
- GlobeNewswire•2 months ago
Oncocyte to Report Third Quarter 2018 Financial Results on November 13, 2018
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the third quarter ended September 30, 2018, on Tuesday, November 13, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, November 13, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments. For all callers, please refer to Conference ID 13684100.
- GlobeNewswire•3 months ago
OncoCyte Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu™ Development Studies
OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided an update on its successful transition to a new diagnostic testing platform and initiation of a series of studies designed to make its DetermaVu™ lung cancer assay available for the medical market in the second half of 2019. OncoCyte has completed its transition to an industry standard Next Generation Sequencing (NGS) diagnostic testing platform, including installation, training and operational qualification. Based on these positive results, OncoCyte has initiated the 700-blood sample Algorithm Development Study to establish a proprietary mathematical algorithm that will be used to interpret test results for DetermaVu™.
Markit•3 months agoSee what the IHS Markit Score report has to say about OncoCyte Corp.
Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding OCX is favorable, with net inflows of $2.50 billion.
Markit•3 months agoSee what the IHS Markit Score report has to say about OncoCyte Corp.
Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding OCX is favorable, with net inflows of $4.08 billion.
Markit•4 months agoSee what the IHS Markit Score report has to say about OncoCyte Corp.
Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding OCX is favorable, with net inflows of $2.22 billion.
Markit•4 months agoSee what the IHS Markit Score report has to say about OncoCyte Corp.
Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding OCX totaled $207 million.
Markit•5 months agoSee what the IHS Markit Score report has to say about OncoCyte Corp.
Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold OCX had net inflows of $687 million over the last one-month.
- Associated Press•5 months ago
OncoCyte: 2Q Earnings Snapshot
On a per-share basis, the Alameda, California-based company said it had a loss of 12 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.85. A year ago, they were trading at ...
- Simply Wall St.•5 months ago
Who Are The Major Shareholders In OncoCyte Corporation (NYSEMKT:OCX)?
In this article, I will take a quick look at OncoCyte Corporation’s (NYSEMKT:OCX) recent ownership structure – an unconventional investing subject, but an important one. A company’s ownership structure isRead More...
Markit•6 months agoSee what the IHS Markit Score report has to say about OncoCyte Corp.
Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding OCX totaled $877 million.
